131 related articles for article (PubMed ID: 25778932)
1. Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells.
Yamanegi K; Kawabe M; Futani H; Nishiura H; Yamada N; Kato-Kogoe N; Kishimoto H; Yoshiya S; Nakasho K
Int J Oncol; 2015 May; 46(5):1994-2002. PubMed ID: 25778932
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Kumanishi S; Yamanegi K; Nishiura H; Fujihara Y; Kobayashi K; Nakasho K; Futani H; Yoshiya S
Int J Oncol; 2019 Jul; 55(1):167-178. PubMed ID: 31180533
[TBL] [Abstract][Full Text] [Related]
3. Sodium Valproate Enhances Semaphorin 3A-mediated Anti-angiogenesis and Tumor Growth Inhibition in Human Osteosarcoma Cells.
Sawai T; Yamanegi K; Nishiura H; Futani H; Tachibana T
Anticancer Res; 2023 Jun; 43(6):2539-2550. PubMed ID: 37247909
[TBL] [Abstract][Full Text] [Related]
4. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.
Xiao T; Fan JK; Huang HL; Gu JF; Li LY; Liu XY
Cell Res; 2010 Mar; 20(3):367-78. PubMed ID: 19918267
[TBL] [Abstract][Full Text] [Related]
5. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.
Zhang N; Wu P; Shayiremu D; Wu L; Shan H; Ye L; Zhao X; Cai J; Jiang WG; Gong K; Yang Y
Int J Oncol; 2013 May; 42(5):1664-73. PubMed ID: 23545578
[TBL] [Abstract][Full Text] [Related]
6. A novel secreted splice variant of vascular endothelial cell growth inhibitor.
Chew LJ; Pan H; Yu J; Tian S; Huang WQ; Zhang JY; Pang S; Li LY
FASEB J; 2002 May; 16(7):742-4. PubMed ID: 11923219
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas.
Jia W; Sander AJ; Jia G; Ni M; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Sep; 33(9):3815-22. PubMed ID: 24023314
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of vascular endothelial growth inhibitor in aged porcine bladder detrusor muscle cells.
Wang M; Zhang N; Wang W; Wang B; Xu Z; Yang Y
Biogerontology; 2013 Oct; 14(5):543-56. PubMed ID: 24030243
[TBL] [Abstract][Full Text] [Related]
9. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
[TBL] [Abstract][Full Text] [Related]
10. Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions.
Bamias G; Evangelou K; Vergou T; Tsimaratou K; Kaltsa G; Antoniou C; Kotsinas A; Kim S; Gorgoulis V; Stratigos AJ; Sfikakis PP
Exp Dermatol; 2011 Sep; 20(9):725-31. PubMed ID: 21672030
[TBL] [Abstract][Full Text] [Related]
11. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA
Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285
[TBL] [Abstract][Full Text] [Related]
12. Death receptor 3 mediates TNFSF15- and TNFα-induced endothelial cell apoptosis.
Xu LX; Grimaldo S; Qi JW; Yang GL; Qin TT; Xiao HY; Xiang R; Xiao Z; Li LY; Zhang ZS
Int J Biochem Cell Biol; 2014 Oct; 55():109-18. PubMed ID: 25161149
[TBL] [Abstract][Full Text] [Related]
13. Expression of DcR3 and its effects in kaposi's sarcoma-associated herpesvirus-infected human endothelial cells.
Yoo S; Jang J; Kim S; Cho H; Lee MS
Intervirology; 2012; 55(1):45-52. PubMed ID: 21293109
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro.
Zhang N; Sanders AJ; Ye L; Kynaston HG; Jiang WG
Anticancer Res; 2010 Jan; 30(1):87-95. PubMed ID: 20150621
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis.
Metheny-Barlow LJ; Li LY
Semin Ophthalmol; 2006; 21(1):49-58. PubMed ID: 16517446
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.
Ge Z; Sanders AJ; Ye L; Jiang WG
Exp Ther Med; 2011 Mar; 2(2):167-172. PubMed ID: 22977485
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Blattmann C; Oertel S; Ehemann V; Thiemann M; Huber PE; Bischof M; Witt O; Deubzer HE; Kulozik AE; Debus J; Weber KJ
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):237-45. PubMed ID: 20646843
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
